CN103721094B - 用于降血压的保健茶 - Google Patents
用于降血压的保健茶 Download PDFInfo
- Publication number
- CN103721094B CN103721094B CN201310461769.9A CN201310461769A CN103721094B CN 103721094 B CN103721094 B CN 103721094B CN 201310461769 A CN201310461769 A CN 201310461769A CN 103721094 B CN103721094 B CN 103721094B
- Authority
- CN
- China
- Prior art keywords
- fructus
- radix
- blood pressure
- herba
- folium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000036772 blood pressure Effects 0.000 title claims abstract description 44
- 230000036541 health Effects 0.000 title claims abstract description 39
- 240000007524 Camellia sinensis var. sinensis Species 0.000 title 1
- 241001122767 Theaceae Species 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 244000235603 Acacia catechu Species 0.000 claims abstract description 18
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 18
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 18
- 210000000582 Semen Anatomy 0.000 claims abstract description 18
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 206010033546 Pallor Diseases 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 14
- 238000004140 cleaning Methods 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- 206010053615 Thermal burn Diseases 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000002829 reduced Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 37
- 230000002354 daily Effects 0.000 abstract description 3
- 210000004185 Liver Anatomy 0.000 description 31
- 210000003734 Kidney Anatomy 0.000 description 26
- 206010020772 Hypertension Diseases 0.000 description 25
- 239000008280 blood Substances 0.000 description 23
- 210000004369 Blood Anatomy 0.000 description 22
- 210000000214 Mouth Anatomy 0.000 description 22
- 230000001737 promoting Effects 0.000 description 18
- 210000004072 Lung Anatomy 0.000 description 15
- 210000000952 Spleen Anatomy 0.000 description 15
- 210000002216 Heart Anatomy 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 208000002173 Dizziness Diseases 0.000 description 8
- 230000000414 obstructive Effects 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 7
- 201000010874 syndrome Diseases 0.000 description 7
- 210000001124 Body Fluids Anatomy 0.000 description 6
- 206010019233 Headache Diseases 0.000 description 6
- 210000002784 Stomach Anatomy 0.000 description 6
- 208000009205 Tinnitus Diseases 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000000056 organs Anatomy 0.000 description 6
- 231100000886 tinnitus Toxicity 0.000 description 6
- 210000004204 Blood Vessels Anatomy 0.000 description 5
- 210000004556 Brain Anatomy 0.000 description 5
- 206010022437 Insomnia Diseases 0.000 description 5
- 230000003276 anti-hypertensive Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000004630 mental health Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 208000008787 Cardiovascular Disease Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 241000668709 Dipterocarpus costatus Species 0.000 description 4
- 208000001848 Dysentery Diseases 0.000 description 4
- 210000003608 Feces Anatomy 0.000 description 4
- 210000001624 Hip Anatomy 0.000 description 4
- 206010022114 Injury Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000025627 positive regulation of urine volume Effects 0.000 description 4
- 230000000268 renotropic Effects 0.000 description 4
- 230000002522 swelling Effects 0.000 description 4
- 206010003549 Asthenia Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010018987 Haemorrhage Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010027327 Menstrual disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000003205 Muscles Anatomy 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000008425 Protein Deficiency Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010068760 Ulcers Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000000994 depressed Effects 0.000 description 3
- 230000000881 depressing Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000003203 everyday Effects 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000002107 myocardial Effects 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001015 Abdomen Anatomy 0.000 description 2
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010013990 Dysuria Diseases 0.000 description 2
- 241000508725 Elymus repens Species 0.000 description 2
- 206010015037 Epilepsy Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 210000003494 Hepatocytes Anatomy 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 206010020937 Hypoaesthesia Diseases 0.000 description 2
- 210000003127 Knee Anatomy 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 231100000614 Poison Toxicity 0.000 description 2
- 206010072736 Rheumatic disease Diseases 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 210000001138 Tears Anatomy 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000001914 calming Effects 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003419 expectorant Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 235000020828 fasting Nutrition 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001047 pyretic Effects 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 230000000552 rheumatic Effects 0.000 description 2
- 230000000630 rising Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000002889 sympathetic Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- SGUAFYQXFOLMHL-ACJLOTCBSA-N 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-4-phenylbutan-2-yl]amino]ethyl]benzamide Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 SGUAFYQXFOLMHL-ACJLOTCBSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010001954 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 229960004980 Betanidine Drugs 0.000 description 1
- NIVZHWNOUVJHKV-UHFFFAOYSA-N Bethanidine Chemical compound CN\C(=N/C)NCC1=CC=CC=C1 NIVZHWNOUVJHKV-UHFFFAOYSA-N 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 210000000621 Bronchi Anatomy 0.000 description 1
- 210000003123 Bronchioles Anatomy 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- 229960002320 Celiprolol Drugs 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 208000006111 Contracture Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 229950007942 Dilevalol Drugs 0.000 description 1
- 206010013781 Dry mouth Diseases 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 229960000873 Enalapril Drugs 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 210000001174 Endocardium Anatomy 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000001780 Epistaxis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 210000000416 Exudates and Transudates Anatomy 0.000 description 1
- 210000000720 Eyelashes Anatomy 0.000 description 1
- 229960003580 Felodipine Drugs 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000003512 Furunculosis Diseases 0.000 description 1
- 206010018830 Haematemesis Diseases 0.000 description 1
- 206010018836 Haematochezia Diseases 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 210000004276 Hyalin Anatomy 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- DAXYUDFNWXHGBE-VKCGGMIFSA-N Isorhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-VKCGGMIFSA-N 0.000 description 1
- DAXYUDFNWXHGBE-HLKYYGKDSA-N Isorhynchophylline Natural products O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H](CC)[C@@H](\C(=C\OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-HLKYYGKDSA-N 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N Ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N Labetalol Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 229960002394 Lisinopril Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 229960004773 Losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N Losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 208000004396 Mastitis Diseases 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229960001597 Nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Nucynt Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 210000003516 Pericardium Anatomy 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010036596 Premature ejaculation Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000008128 Pulmonary Tuberculosis Diseases 0.000 description 1
- 229960003401 Ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N Ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N Reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 229960000764 Rilmenidine Drugs 0.000 description 1
- CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical compound C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 210000001113 Umbilicus Anatomy 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 231100000611 Venom Toxicity 0.000 description 1
- 210000001048 Venoms Anatomy 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 206010052769 Vertigos Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001166 anti-perspirant Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N benzazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000001488 breeding Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000036545 exercise Effects 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 229930003944 flavones Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 230000001631 hypertensive Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- YGAMIEYKXHAVBP-UHFFFAOYSA-N molecular hydrogen;hydrochloride Chemical compound Cl.[H][H] YGAMIEYKXHAVBP-UHFFFAOYSA-N 0.000 description 1
- 229960003938 moxonidine Drugs 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000004873 systolic arterial blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000002936 tranquilizing Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000002747 voluntary Effects 0.000 description 1
Abstract
Description
SBp | DBp | |
服用前 | 157.32±10.03 | 95.49±3.91 |
服用后 | 136.17±8.22 | 83.19±2.01 |
组别 | n | 显效 | 有效 | 无效 | 总有效 |
治疗组 | 70 | 42(60.0) | 25(35.7) | 3(4.3) | 67(95.7) |
服用前 | 15.19±2.14 |
服用后 | 7.51±1.97 |
组别 | n | 显效 | 有效 | 无效 | 总有效 |
治疗组 | 70 | 40(57.1) | 27(38.6) | 3(4.3) | 67(95.7) |
SF(满分20分) | MH(满分20分) | QOL(满分130分) |
服用前 | 13.19±2.71 | 14.29±2.18 | 98.93±10.028 --> |
服用后 | 15.74±2.94 | 16.98±2.01 | 107.02±10.91 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310461769.9A CN103721094B (zh) | 2013-09-28 | 2013-09-28 | 用于降血压的保健茶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310461769.9A CN103721094B (zh) | 2013-09-28 | 2013-09-28 | 用于降血压的保健茶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103721094A CN103721094A (zh) | 2014-04-16 |
CN103721094B true CN103721094B (zh) | 2016-07-13 |
Family
ID=50445555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310461769.9A Expired - Fee Related CN103721094B (zh) | 2013-09-28 | 2013-09-28 | 用于降血压的保健茶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103721094B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104258135A (zh) * | 2014-09-23 | 2015-01-07 | 苏州市天灵中药饮片有限公司 | 用于降血压降血脂的保健软胶囊及其制备方法 |
CN104304596A (zh) * | 2014-11-16 | 2015-01-28 | 久美彭措 | 一种采用食用植物作为成分组合而成的降血糖代用茶的制备方法 |
CN105012385A (zh) * | 2015-07-28 | 2015-11-04 | 红河州吉昌生物科技有限公司 | 改进型补肝肾降血压胶囊 |
CN109953152A (zh) * | 2017-12-22 | 2019-07-02 | 甘肃渭水源药业科技有限公司 | 一种用黄芪花作原料的花茶及其制备方法 |
CN108617818A (zh) * | 2018-08-16 | 2018-10-09 | 李文霞 | 一种降血压的保健茶 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095952A (zh) * | 1993-06-04 | 1994-12-07 | 陈顺志 | 一种新型药茶的生产方法 |
CN100400078C (zh) * | 2006-06-28 | 2008-07-09 | 陈志忠 | 一种治疗高血压、高血脂、高血糖的中草药剂 |
CN102949615A (zh) * | 2012-12-04 | 2013-03-06 | 南通瑞鑫电子电器有限公司 | 一种治疗高血压的药 |
CN103041070B (zh) * | 2012-12-31 | 2014-11-05 | 青岛华仁技术孵化器有限公司 | 一种银杏叶降脂降压保健品及其制备方法 |
CN103120766B (zh) * | 2013-01-29 | 2014-05-28 | 王超庆 | 一种治疗高血压的中药组合物 |
-
2013
- 2013-09-28 CN CN201310461769.9A patent/CN103721094B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103721094A (zh) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104606513B (zh) | 一种治疗心脑血管疾病的中药及其制备方法 | |
CN103721094B (zh) | 用于降血压的保健茶 | |
CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
CN103520505A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
CN104906403A (zh) | 一种降压降脂的罗布麻叶保健口服液及其制备方法 | |
CN104432386B (zh) | 一种防治腰膝酸软、筋骨无力的桑寄生口服液及其制备方法 | |
CN103550713B (zh) | 一种治疗高血压的中药 | |
CN103432274B (zh) | 一种治疗偏头痛的药物及其制备方法 | |
CN105169078A (zh) | 一种治疗糖尿病的中药组合物 | |
CN105457001A (zh) | 一种治疗小儿多动症的药物及其制备方法 | |
CN104758572A (zh) | 一种治疗痰饮阻肺型心功能不全的药物及其制备方法 | |
CN104689240A (zh) | 一种治疗气滞血瘀型黄褐斑的药物及其制备方法 | |
CN104435535A (zh) | 一种治疗ⅱ型糖尿病的保健药品 | |
CN105381285A (zh) | 中药复合降压保健茶 | |
CN104223062B (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 | |
CN103721182A (zh) | 用于治疗高血压的中药组合物 | |
CN105327145A (zh) | 治疗高血压性脑出血的组合物及其制备方法 | |
CN105343779A (zh) | 降血压保护血管中药组合物 | |
CN105362907A (zh) | 一种治疗乳腺囊肿的泡腾片及其制备方法 | |
CN105709071A (zh) | 用于治疗产后便秘的药物及其制备方法 | |
CN104606571A (zh) | 一种生津止渴鲜菠菜根代茶饮及制备方法 | |
CN104258135A (zh) | 用于降血压降血脂的保健软胶囊及其制备方法 | |
CN108159365A (zh) | 一种用于治疗冠心病心肌缺血的中药组合物及其制备方法 | |
CN103520644A (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160617 Address after: Qingdao City, Shandong province 266033 Taiwan Liu Road No. 138 B Applicant after: Yang Gaolin Address before: 266071 Shandong city of Qingdao province Hongkong City Road No. 32 Minmetals building room 801-A Applicant before: Qingdao Huaren Technology Incubator Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 542899 No. 25 Jianshe Middle Road, the Guangxi Zhuang Autonomous Region, Hezhou Patentee after: Yang Gaolin Address before: Qingdao City, Shandong province 266033 Taiwan Liu Road No. 138 B Patentee before: Yang Gaolin |
|
CP02 | Change in the address of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180529 Address after: 511401 304, room 3, Longji building, 16 Ping Kang Road, Panyu District, Guangzhou, Guangdong. Patentee after: Guangzhou Zhonghui agricultural science and Technology Co., Ltd. Address before: 542899 No. 25 Jianzhong Road, Hezhou, the Guangxi Zhuang Autonomous Region. Patentee before: Yang Gaolin |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160713 Termination date: 20180928 |
|
CF01 | Termination of patent right due to non-payment of annual fee |